Korea MSD’s Keytruda (pembrolizumab) has made significant strides in expanding its reimbursement coverage, securing approval for 11 indications, including gastric and esophageal 해외 바카라 사이트s. The announcement follows the results of the first 2025 Severe (해외 바카라 사이트) Disease Review Committee, disclosed by the Health Insurance Review & Assessment Service (HIRA) on February 12.
The approved indications include HER2-positive and HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, esophageal 해외 바카라 사이트, endometrial 해외 바카라 사이트, colorectal 해외 바카라 사이트, recurrent head and neck squamous cell carcinoma, cervical 해외 바카라 사이트, triple-negative breast 해외 바카라 사이트, small intestine 해외 바카라 사이트, and biliary tract 해외 바카라 사이트. For HER2-negative cases, a requirement of a CPS score of 10 or higher was applied.
Previously, MSD had submitted additional financial burden-sharing data after the final committee meeting last year deferred Keytruda’s reimbursement. In response, the company provided supplementary clinical data and revised financial proposals. Patient advocacy groups also urged approval, highlighting that delays restricted patients’ access to critical treatment. With the latest decision, MSD is expected to accelerate efforts to further expand Keytruda’s reimbursement in gastric 해외 바카라 사이트.
The committee’s review yielded mixed results for other therapies. Pfizer Korea’s Methotrexate secured reimbursement for intraocular lymphoma, while Elrexfio, a multiple myeloma treatment, failed its initial review and must reapply. Novartis’ Scemblix was approved for adult patients with chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) who have been treated with at least two prior tyrosine kinase inhibitors (TKIs). However, Padcev for urothelial carcinoma and Zolbetuximab for gastric adenocarcinoma were denied reimbursement.
